Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III evaluation of TB-PPD for tuberculosis infection diagnosis in individuals aged 6 years and above
CTR20250317Phase 3Active
- Sponsor
- Kernal Biologics
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tuberculin purified protein derivative in Tuberculosis (TB), pulmonary tuberculosis (TB), extrapulmonary tuberculosis (EPTB), nontuberculous mycobacterial lung disease, nontuberculous mycobacteria infection, sponsored by Kernal Biologics. Started Mar 2026; status: active.
02
Drugs
tuberculin purified protein derivative
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)extrapulmonary tuberculosis (EPTB)nontuberculous mycobacterial lung diseasenontuberculous mycobacteria infection
Beyond the preview
Go deeper on CTR20250317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250317.